Qureight

Data curation to accelerate drug development.

Qureight accelerates clinical trial development through data curation and AI to bring better therapies to patients with high unmet needs.

Our customers, including AstraZeneca and Vicore, use us to support billion dollar decisions, pushing boundaries in respiratory disease research.

Clinical trial data analysis is broken, risking failed drugs and huge financial losses, as evidenced by Roche's failed $1.4Bn investment and $200M trial loss.

Qureight offers a single platform to streamline clinical trial data, enabling faster, more accurate drug development decisions by consolidating and analyzing data with AI.

Our key products include AI image analysis, virtual trial arms, and Central Read System, all designed to enhance clinical trial efficiency and decision-making.

The competitive landscape is fragmented, with CROs, Pharma, and Med tech AI struggling with siloed data, lack of real-world datasets, and technological limitations.

The global lung and heart clinical trials market is projected to grow significantly, with Qureight positioned to capitalize on over 3200 trials per year.

Our leadership is a unique blend of clinicians and software engineers, providing expertise in both healthcare and technology.

We are raising $7.5M to enhance our imaging and data integration, expand our data lake, and support increased clinical trials, driving growth.